Cynosure Group LLC Sells 32,545 Shares of DexCom, Inc. (NASDAQ:DXCM)

Cynosure Group LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 89.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,687 shares of the medical device company's stock after selling 32,545 shares during the period. Cynosure Group LLC's holdings in DexCom were worth $287,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Cinctive Capital Management LP purchased a new stake in DexCom during the 4th quarter worth about $6,097,000. Huntington National Bank boosted its position in shares of DexCom by 94.5% in the fourth quarter. Huntington National Bank now owns 2,748 shares of the medical device company's stock worth $214,000 after buying an additional 1,335 shares during the period. Geode Capital Management LLC grew its position in DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after acquiring an additional 56,094 shares in the last quarter. Tradewinds LLC. acquired a new stake in DexCom during the 4th quarter valued at $278,000. Finally, HighPoint Advisor Group LLC acquired a new stake in shares of DexCom during the fourth quarter worth approximately $427,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last quarter. Corporate insiders own 0.30% of the company's stock.

Remove Ads

DexCom Trading Up 10.1 %

NASDAQ:DXCM traded up $6.15 on Wednesday, hitting $66.84. 6,696,624 shares of the stock were exchanged, compared to its average volume of 4,149,361. The company's 50-day moving average price is $77.74 and its 200 day moving average price is $76.63. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $141.25. The stock has a market capitalization of $26.21 billion, a price-to-earnings ratio of 46.74, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on DXCM. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.